Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Accelerate Diagnostics (AXDX) reported a Q3 loss of $0.59 per share, missing the Zacks Consensus Estimate of a $0.47 loss. This is an improvement from the $0.92 loss per share a year ago.
November 08, 2024 | 12:00 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Accelerate Diagnostics reported a Q3 loss of $0.59 per share, which was worse than the expected $0.47 loss. However, this is an improvement from the $0.92 loss per share a year ago.
The reported loss per share was worse than expected, which is likely to negatively impact the stock price in the short term. However, the improvement from last year's loss may mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100